José Sarrà, Tarragona, Spain
Isabel Krsnik, Madrid, Spain
Experts’ discussion on the Treatment of Patients with AL myloidosis non-eligible for ASCT: burning questions
Morie A. GertzRochester, MN, USA
Shaji Kumar, Rochester, MN, USA
Monique C. Minnema, Utrecht, the Netherlands
Paolo Milani, Pavia, Italy
Maria Teresa Cibeira, Barcelona, Spain
Arnaud Jaccard, Limoges, France
Maria Gavriatopoulou, Athens, Greece
• Best initial therapy for fit patients
• Best inicial therapy for unfit patients
• When to start therapy at relapse or progression
• Treatment at first relapse
• Treatment at later relapses or refractory disease
• Best novel emerging agents
• Role of anti-amyloid therapy
Hereditary Transthyretin Amyloidosis
Mathew Maurer, New York, USA
Mechanisms of organ damage in ATTR amyloidosis
Julian Gillmore, London, UK
RNA interference for gene expression control in ATTR amyloidosis
Laura Obici, Pavia, Italy
Hereditary ATTR amyloidosis: role of RNA interference therapy
David Adams, Paris, France
Hereditary ATTR Amyloidosis: Clinical Features and Follow-up
Ernst Hund, Heidelberg, Germany
Lucía Galán, Madrid, Spain
Clinical features of polyneuropathy in hereditary amyloidosis
Yukio Ando, Kumamoto, Japan
Red-flags for early diagnosis in hereditary amyloidosis
Yoshiki Sekijima, Matsumoto, Japan
The global prevalence of ATTR amyloidosis
Other Manifestations in ATTR Amyloidosis
Jonas Wixner, Umeå, Sweden
Follow-up, polyneuropathy detection, de novo manifestations and treatment after domino liver transplantation
Laura Obici, Pavia, Italy
 AA and other forms of Amyloidosis
Martha Skinner, Boston, USA
Julian Gillmore, London, UK
AA amyloidosis: current incidence and clinical presentation
Alberto Martinez-Vea, Tarragona, Spain
AA amyloidosis: management
Luís Quintana, Barcelona, Spain
AA amyloidosis associated with autoinflammatory diseases
Helen Lachmann, London, UK
Localized amyloidosis
Hereditary non-transthyretin amyloidosis
Philip N. Hawkins, London, UK
LECT2-associated renal amyloidosis
Tamer Rezk, London, UK